Thus, our driving hypothesis is that reduction of inflammatory pathways via inhibition of activity and/or decreased COX-2 expression results in re-expression of SIM2s and may be one mechanism for preventing progression of DCIS to invasive or metastatic breast cancer [23]. The gene discussed is PTGS2; the disease is ductal breast carcinoma in situ.